Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05851859
Other study ID # 2022/CHU/35
Secondary ID 2023-A00796-39
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date March 29, 2024
Est. completion date November 1, 2026

Study information

Verified date February 2024
Source Centre Hospitalier Universitaire de la Réunion
Contact Léa BRUNEAU
Phone 02 62 90 68 83
Email lea.bruneau@chu-reunion.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Despite the controversy, on October 6, 2021, the World Health Organization (WHO) recognized Long Coronavirus disease (COVID) by officially defining it: " symptoms appeared 3 months after the onset of the primary infection by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), persisting for at least 2 months and which cannot be explained by any other condition ". Long COVID can affects any type of patient and has polymorphic and fluctuating symptoms over time. The Reunion Island is a French overseas department located in the Indian Ocean accounting more than 860,000 inhabitants. It has recorded since March 11, 2020, nearly 491,825 cases of COVID-19 and 961 deaths of hospitalized patients. Reunion's population is multi-ethnic and younger than the metropolitan France's one. It also has a higher prevalence of obesity and type 2 diabetes, two serious form factors of COVID-19. This specific context makes this island a particular study site for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Long COVID. In addition, some studies have confirmed the involvement of the autonomic nervous system (ANS) in the symptomatology of Long COVID and demonstrated that patients with a Long COVID present a dysfunction of their ANS which is objectified by a reduced Heart Rate Variability (HRV). The regulation of heart rate by the ANS is strongly favored by respiration. A regular slow and deep breathing training helps to adjust the baroreflex, which connect heart rate, breathing and blood pressure. The result of this training is an induced state called "cardiac coherence" (CC). The investigator therefore hypothesize that respiratory training to CC could "re-educate" the ANS and durably improve the symptomatology of patients with Long COVID.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 200
Est. completion date November 1, 2026
Est. primary completion date September 1, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients over the age of 18, - living in Reunion and - having a diagnosis of Long COVID according to the World Health Organization (WHO) definition will be included in this study. - These patients must attest to their primary infection with Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and present a negative antigen test at the time of inclusion. Exclusion Criteria: Patients: - with a chronic or disabling respiratory pathology preventing respiratory training (asthma, Chronic Obstructive Pulmonary Disease (COPD), active tuberculosis, pulmonary sequelae of COVID-19, etc.) practicing or having practiced a regular respiratory control technique (yoga, Cardiac coherence training, etc.) in the last 6 months - taking a beta-blocker, betamimetic, anti-arrhythmic, morphine, antidepressant treatment (Escitalopram) - having a pacemaker or severe heart disease - Current and known pregnancy or breastfeeding woman - with a cognitive deficit - under guardianship/curators or under judicial protection

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Cardiac coherence
Use of Cardiac coherence (complementary respiratory training) during 6 month

Locations

Country Name City State
France CHU de la Réunion Saint-Denis
France CHU de la Réunion Saint-Pierre

Sponsors (1)

Lead Sponsor Collaborator
Centre Hospitalier Universitaire de la Réunion

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluation of the effectiveness of a respiratory training to cardiac coherence on the reduction in the symptomatology of patients with Long COVID. mean score on the Long COVID Symptom Tool (ST) scale Score 0 to 53 / Higher score mean worse outcome 6 months
Secondary Evaluation of the effectiveness of a respiratory training to cardiac coherence on the decrease of overall symptoms over time Long COVID Symptom Tool (ST) scale Score 0 to 53 / Higher score mean worse outcome T0, 1 month, 2 months, 3 months, 6 months
Secondary Evaluation of the effectiveness of a respiratory training to cardiac coherence on the decrease of specifics symptoms : fatigue The 11-item Chalder Fatigue Scale (CFS-11) score 0 to 11 / Higher score mean worse outcome 3 months, 6 months
Secondary Evaluation of the effectiveness of a respiratory training to cardiac coherence on the decrease of specifics symptoms : dyspnoea Modified Medical Research Council (MMRC) dyspnoea scale score 0 to 5 / Higher score mean worse outcome 3 months, 6 months
Secondary Evaluation of the effectiveness of a respiratory training to cardiac coherence on the decrease of specifics symptoms : Anxiety and Depression Hospital Anxiety and Depression scale (HADS) Score 0 to 42 / Higher score mean worse outcome 3 months, 6 months
Secondary Evaluation of the effectiveness of a respiratory training to cardiac coherence on the decrease of specifics symptoms : cognitive disorders Montreal Cognitive Assessment (MoCA) Score 0 to 30 / Higher score mean better outcome 3 months, 6 months
Secondary Evaluation of the effectiveness of a respiratory training to cardiac coherence on the decrease of specifics symptoms : Post Traumatic Stress Disorder Posttraumatic Stress Disorder Checklist for Diagnostic and statistical manual of mental disorders, version 5 (PCL-5) Score 0 to 80 / Higher score mean worse outcome 3 months, 6 months
Secondary Evaluation of the effectiveness of a respiratory training to CC on the impact of the disease on daily life Long COVID Impact Tool (IT) scale Score 0 to 60 / Higher score mean worse outcome T0, 1 month, 2 months, 3 months, 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT05926505 - Safety and Efficacy of Anakinra Treatment for Patients With Post Acute Covid Syndrome Phase 2/Phase 3
Recruiting NCT04872309 - MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
Completed NCT05552612 - Health-related Quality of Life and Long COVID
Completed NCT05531019 - COVID-19 Sequelae: Treatment and Monitoring. A Dietary Supplement Based on Sea Urchin Eggs With Echinochroma A N/A
Not yet recruiting NCT04949386 - Safety, Tolerability and Efficacy of S-1226 in Post-COVID-19 Subjects With Persistent Respiratory Symptoms. Phase 2
Recruiting NCT06118112 - Living With Long COVID: LONGCOVID-EXPERIENCE
Completed NCT05185674 - Sociodemographic, Clinical, Quality of Life and Health Care Conditions in COVID-19 Survivors.
Active, not recruiting NCT05965739 - RECOVER-NEURO: Platform Protocol, Appendix_A to Measure the Effects of BrainHQ, PASC CoRE and tDCS Interventions on Long COVID Symptoms N/A
Active, not recruiting NCT05965752 - RECOVER-NEURO: Platform Protocol to Measure the Effects of Cognitive Dysfunction Interventions on Long COVID Symptoms N/A
Completed NCT05812209 - Stellate Ganglion Block to Treat Long COVID 19 Case Series
Recruiting NCT05606211 - Pain in Long COVID-19: The Role of Sleep
Active, not recruiting NCT05713266 - Using Data From a Multisensor Rapid Health Assessment Device to Predict Decompensation in Long COVID (AIDI)
Completed NCT05679505 - Vagus Nerve Stimulation for Post-COVID Syndrome N/A
Completed NCT05601180 - Evaluation of the Efficacy of Respicure® (Resveratrol / Quercetin) in the Management of Respiratory Conditions Including Asthma,COPD and Long COVID. N/A
Not yet recruiting NCT06045338 - Mind Body Intervention for Long COVID N/A
Recruiting NCT06091358 - Inspiratory Muscle Training in People With Long COVID-19- A Pilot Investigation. N/A
Recruiting NCT05566392 - Longterm Influence of Pediatric Long COVID Syndrome
Recruiting NCT05855369 - Smell Training and Trigeminal Nerve Stimulation for COVID-related Smell Loss Phase 2/Phase 3
Recruiting NCT05572346 - Digital App for Telerehabilitation in Respiratory Diseases
Recruiting NCT06316843 - Valacyclovir Plus Celecoxib for Post-Acute Sequelae of SARS-CoV-2 Phase 2